Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways


ÇAVDAR Z., URAL ÖZKAN C., Kocak A., ARSLAN Ş., Ersan S., ÖZBAL S., ...More

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.44, no.4, pp.452-461, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1515/tjb-2018-0155
  • Journal Name: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.452-461
  • Keywords: Paricalcitol, Ischemia, Kidney, p38 MAPK, PI3K/Akt, ISCHEMIA-REPERFUSION INJURY, INDUCED KIDNEY INJURY, NF-KAPPA-B, ISCHAEMIA/REPERFUSION INJURY, INFLAMMATION, ERYTHROPOIETIN, APOPTOSIS
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objective: This study aimed to investigate the renoprotective effects of paricalcitol, a synhetic vitamin D analog, through its possible roles on p38 MAPK and PI3K/Akt signaling pathways to prevent oxidative stress, inflammation and apoptosis during renal I/R.